

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 09, 2024, 01:13 PM
Patient ID / UHID : 8052315/RCL7248889	Barcode No : ZC666939
Referred By : Dr. X	Report Status : Final Report
Sample Type : Whole blood EDTA	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**Everolimus**

EVEROLIMUS LC-MS/MS	4.5	ug/L	3.0 - 8.0
------------------------	-----	------	-----------

**Interpretation:**

ORGAN TRANSPLANT	THERAPEUTIC RANGE in ug/L
Kidney (Everolimus in combination with Cyclosporine)	3-8
Liver (Everolimus in combination with Tacrolimus )	3-8
	Toxic value : > 15

**Note**

1. Therapeutic range is based on whole blood specimen drawn 12 hrs post dose or prior to next dose (trough)
2. The recommended concentration is for kidney transplant patients on triple therapy with Cyclosporine, Corticosteroids & Everolimus.
3. Everolimus Whole blood concentrations can be measured by either chromatographic (LC-MS/MS) or immunoassay (CLIA) methodologies. These two techniques are not directly interchangeable and the measured drug level depends on the methodology used. Reference ranges are different for the two methodologies. Generally CLIA has a positive bias as compared with LC-MS/MS due to cross reacting antibodies with the drug metabolites.

**Comments**

LC-MS/MS is considered the most sensitive, specific and precise technology for monitoring immunosuppressants . Therapeutic drug monitoring (TDM) is commonly used to help maintain drug levels within the concentration range in which the drug exerts its clinical effect with minimal adverse reactions. Everolimus is a synthetically produced derivative of Sirolimus and is a potent immunosuppressive drug specially when used in conjunction with Cyclosporine. It acts by suppressing cytokine driven T lymphocyte proliferation thereby inhibiting progression from G1 to S phase of the cell cycle. It is rapidly absorbed from the GI tract achieving peak concentration in whole blood in about 3 hours. The elimination half life of Everolimus is 24 hours. Cyclosporine inhibits the metabolism of Everolimus, but Everolimus does not affect the metabolism of Cyclosporine. The primary side effect of therapy is hyperlipidemia.

**Indications for testing**

- Immunosuppressant dose optimization
- Failure to respond to immuosuppressants
- Signs or Symptoms consistent with inadequate or excessive immunosuppression
- Changes to concomitant medications or other variables that affect pharmacokinetics

\*\*\* End Of Report \*\*\*

**Disclaimer: Method given in report are only indicative and can be changed depending upon type of machine and kit available at time of testing.**

**Not all tests at all locations are under NABL scope. Availability of tests under NABL scope varies from lab to lab.**



**Dr. Dummy**



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI  
 Processing Lab :-

# Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

---

## DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.